• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

35.81 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 556
Open 35.81
Bid (Size) 33.50 (1)
Ask (Size) 38.28 (1)
Prev. Close 35.81
Today's Range 35.81 - 35.81
52wk Range 22.61 - 47.32
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
October 15, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity
October 14, 2025
Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout. 
Via Chartmill

Performance

YTD
-11.4%
-11.4%
1 Month
+10.9%
+10.9%
3 Month
+47.9%
+47.9%
6 Month
+15.0%
+15.0%
1 Year
+3.1%
+3.1%

More News

Read More
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics
October 08, 2025
Via Chartmill
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
September 28, 2025
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For August 6, 2025
August 06, 2025
Via Benzinga
Earnings Scheduled For May 7, 2025
May 07, 2025
Via Benzinga
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
September 24, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
September 09, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 29, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
August 27, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
August 26, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential
August 13, 2025
Via Chartmill
Veracyte (VCYT) Q2 Revenue Jumps 14%
August 07, 2025
Via The Motley Fool
Veracyte Announces Second Quarter 2025 Financial Results
August 06, 2025
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
July 26, 2025
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals
July 21, 2025
Via Chartmill
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
July 17, 2025
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
July 08, 2025
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
June 21, 2025
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
June 07, 2025
Via Benzinga
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
May 28, 2025
From Veracyte, Inc.
Via Business Wire
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology
May 28, 2025
Via Chartmill
Veracyte to Participate in Upcoming Investor Conferences
May 20, 2025
From Veracyte, Inc.
Via Business Wire
Breaking Down Veracyte: 7 Analysts Share Their Views
May 08, 2025
Via Benzinga
Veracyte Announces First Quarter 2025 Financial Results
May 07, 2025
From Veracyte, Inc.
Via Business Wire

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 35.81
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 10/16/25 04:00 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 2.42B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 2B shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap